@article{fdi:010090159,
  title = {{T}arget product profile : {T}rypanosoma brucei gambiense test for low-prevalence settings},
  author = {{P}riotto, {G}. and {F}ranco, {J}. {R}. and {L}ejon, {V}eerle and {B}uscher, {P}. and {M}atovu, {E}. and {N}dung'u, {J}. and {B}ieler, {S}. and {M}umba, {D}. and {V}an {R}eet, {N}. and {V}erle, {P}. and {J}amonneau, {V}incent and {S}imarro, {P}. {P}. and {E}beja, {A}. {K}. and {S}ankara, {D}. and {D}agne, {D}. {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{H}aving caused devastating epidemics during the 20th century, the incidence of life-threatening human {A}frican trypanosomiasis has fallen to historically low levels as a result of sustained and coordinated efforts over the past 20 years. {H}umans are the main reservoir of one of the two pathogenic trypanosome subspecies, {T}rypanosoma brucei gambiense, found in western and central {A}frica. {T}he expected advent of a safe and easy-to-use treatment to be given to seropositive but microscopically unconfirmed individuals would lead to further depletion; in the meantime, the presence of {T}. b. gambiense infection in the community must be monitored to allow the control strategy to be adapted and the elimination status to be assessed. {T}he {W}orld {H}ealth {O}rganization has therefore developed a target product profile that describes the optimal and minimal characteristics of an individual laboratory-based test to assess {T}. b. gambiense infection in low-prevalence settings. {D}evelopment of the target product profile involved the formation of a {N}eglected {T}ropical {D}iseases {D}iagnostics {T}echnical {A}dvisory {G}roup and a subgroup on human {A}frican trypanosomiasis diagnostic innovation needs, and an analysis of the available products and development pipeline. {A}ccording to the product profile, the test should ideally: (i) require a minimally invasive or non-invasive specimen, collectable at peripheral facilities by minimally trained health workers; (ii) demonstrate good sensitivity and high specificity; (iii) have a stability of samples allowing transfer to reference laboratories preferably without cold chain; (iv) be stable over a wide range of environmental conditions for more than 2 years; and (v) after marketing, be available at low cost for at least 7 years.},
  keywords = {{AFRIQUE} {DE} {L}'{OUEST} ; {AFRIQUE} {CENTRALE}},
  booktitle = {},
  journal = {{B}ulletin of the {W}orld {H}ealth {O}rganization},
  volume = {101},
  numero = {8},
  pages = {541--545},
  ISSN = {0042-9686},
  year = {2023},
  DOI = {10.2471/blt.23.290176},
  URL = {https://www.documentation.ird.fr/hor/fdi:010090159},
}